acute myeloid leukaemia

News

Kura Oncology and Kyowa Kirin logos with Komzifti pill bottle

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

News

Ipsen buys ImCheck, adding mid-stage leukaemia drug

Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

Operating theatre with nurse and patient under anaesthetic

ASH: Stem cell transplant study exposes US zip-code lottery

Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.

News

Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia

Daiichi Sankyo's FLT3 inhibitor Vanflyta has been recommended for NHS use as a treatment for a specific form of acute myeloid leukaemia (AML) in England and Wales, the first countries in Eu

News

Actinium's radioligand filing plans scuppered by FDA

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radiol

Kura scores FDA okay for rival to Syndax's leukaemia drug

Ipsen buys ImCheck, adding mid-stage leukaemia drug

Ignota vacuums up Kronos Bio's drug programmes

ASH: Stem cell transplant study exposes US zip-code lottery

Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia

Actinium's radioligand filing plans scuppered by FDA

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

acute myeloid leukaemia

Editor's Picks